Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 13/20 | 0.52 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22175381 | 0.95 | SIGMAR1 (0.55) | CXCR4CXCL12SIGMAR1KDM4EHRH4 | |
| SCHEMBL27461328 | 0.93 | SIGMAR1 (0.52) | CXCR4CXCL12SIGMAR1KDM4EHRH4 | |
| SCHEMBL25963986 | 0.88 | SIGMAR1 (0.47) | CXCR4CXCL12SIGMAR1KDM4EHRH4 | |
| SCHEMBL7013588 | 0.88 | — | — | |
| SCHEMBL9417435 | 0.88 | CXCR4 (0.61) | CXCR4CXCL12KDM4EHRH4HRH3 | |
| SCHEMBL17733777 | 0.88 | CXCR4 (0.61) | CXCR4CXCL12KDM4EHRH4HRH3 | |
| SCHEMBL5348992 | 0.86 | RAD52 (0.47) | CXCR4CXCL12SIGMAR1KDM4EHRH3 | |
| Hydrochloric Acid SCHEMBL9714202 | 0.85 | CXCR4 (0.59) | CXCR4CXCL12KDM4ELMNAHRH4 | |
| SCHEMBL11523136 | 0.85 | CXCR4 (0.57) | CXCR4CXCL12KDM4EHRH4HRH3 | |
| SCHEMBL14508591 | 0.83 | RAD52 (0.44) | CXCR4CXCL12SIGMAR1KDM4ERAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119058235-A | Fluid ejection head, method for manufacturing fluid ejection head, fluid ejection assembly, and fluid ejection device | 株式会社理光 | 2024-12-03 | — | — | CN | disclosed |
| WO-2018132326-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2018-07-19 | — | — | WO | disclosed |
| US-20180186808-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME LLC | 2018-07-05 | — | — | US | disclosed |
| US-9944654-B2 | Nargenicin compounds and uses thereof as antibacterial agents | MERCK SHARP & DOHME CORP. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170305924-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | US | disclosed |
| CN-102037076-B | One-liquid type cyanate epoxy composite resin composition | ADEKA CORP | 2014-05-28 | — | — | CN | disclosed |
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| CN-102037076-A | One-liquid type cyanate epoxy composite resin composition | ADEKA CORP | 2011-04-27 | — | — | CN | disclosed |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | disclosed |
| US-20080300189-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION | DIAKINE THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300189-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION | DIAKINE THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-7393827-B2 | Pharmaceutical compositions and methods for restoring β-cell mass and function | DIAKINE THERAPEUTICS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393827-B2 | Pharmaceutical compositions and methods for restoring β-cell mass and function | DIAKINE THERAPEUTICS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7348427-B2 | Antipathogenic benzamide compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7301037-B2 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | GENESOFT, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070105135-A1 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | GENESOFT PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| WO-2006018284-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | IRF3, BCL3, L3MBTL3 | CXCR4 651/4885CXCL12 3971/4885SIGMAR1 1735/4885 |
| US-20180186808-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | NRDC, MME, NME2 | CXCR4 2938/4885CXCL12 1429/4885SIGMAR1 3960/4885 |
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | CXCR4 3096/4885CXCL12 905/4885SIGMAR1 4638/4885 |
| US-20170305924-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | NRDC, MME, NME2 | CXCR4 2938/4885CXCL12 1429/4885SIGMAR1 3960/4885 |
| US-20070105135-A1 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | POLRMT, PCNA, SARS1 | CXCR4 2901/4885CXCL12 2549/4885SIGMAR1 3997/4885 |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | CXCR4 2923/4885CXCL12 757/4885SIGMAR1 4729/4885 |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | CTSS, CTSZ, CTSF | CXCR4 644/4885CXCL12 1674/4885SIGMAR1 4070/4885 |
| US-20080300189-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION | IAPP, PNLIP, AMY2A | CXCR4 789/4885CXCL12 55/4885SIGMAR1 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.